Utilization of Omeprazole To Augment Subtherapeutic Voriconazole Concentrations for Treatment of Aspergillus Infections

被引：30

作者：

Boyd, Natalie K. ^{[1
]}

Zoellner, Cindy L. ^{[1
,2
]}

Swancutt, Mark A. ^{[1
,2
]}

Bhavan, Kavita P. ^{[1
,2
]}

机构：

[1] Parkland Hlth & Hosp Syst, Dallas, TX USA

[2] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2012年 / 56卷 / 11期

关键词：

PHARMACOKINETICS; EFFICACY; THERAPY; SAFETY;

D O I：

10.1128/AAC.00700-12

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Voriconazole is the preferred antifungal agent for Aspergillus infections. Therapeutic drug monitoring is recommended to achieve target concentrations and prevent toxicity. However, variable pharmacokinetics, cytochrome P450 polymorphisms, and extensive drug-drug interactions can contribute to subtherapeutic concentrations. We report a voriconazole "boosting" effect of omeprazole to achieve target concentrations for the treatment of Aspergillus in a patient who had persistently subtherapeutic trough concentrations.

引用

收藏

页码：6001 / 6002

页数：2

相关论文

共 11 条

[1] Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis [J].

Hamada, Yukihiro ;

Seto, Yoshinori ;

Yago, Kazuo ;

Kuroyama, Masakazu .

JOURNAL OF INFECTION AND CHEMOTHERAPY, 2012, 18 (04) :501-507

[2] Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis [J].

Herbrecht, R ;

Denning, DW ;

Patterson, TF ;

Bennett, JE ;

Greene, RE ;

Oestmann, JW ;

Kern, WV ;

Marr, KA ;

Ribaud, P ;

Lortholary, O ;

Sylvester, R ;

Rubin, RH ;

Wingard, JR ;

Stark, P ;

Durand, C ;

Caillot, D ;

Thiel, E ;

Chandrasekar, PH ;

Hodges, MR ;

Schlamm, HT ;

Troke, PF ;

de Pauw, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (06) :408-415

[3]

Ko JW, 1997, DRUG METAB DISPOS, V25, P853

[4] Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes [J].

Pascual, Andres ;

Calandra, Thierry ;

Bolay, Saskia ;

Buclin, Thierry ;

Bille, Jacques ;

Marchetti, Oscar .

CLINICAL INFECTIOUS DISEASES, 2008, 46 (02) :201-211

[5]

Pfizer Inc, 2010, VFEND US PRESCR INF

[6] Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens [J].

Purkins, L ;

Wood, N ;

Ghahramani, P ;

Greenhalgh, K ;

Allen, MJ ;

Kleinermans, D .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (08) :2546-2553

[7] Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy [J].

Scott, S. A. ;

Sangkuhl, K. ;

Gardner, E. E. ;

Stein, C. M. ;

Hulot, J-S ;

Johnson, J. A. ;

Roden, D. M. ;

Klein, T. E. ;

Shuldiner, A. R. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 90 (02) :328-332

[8] Voriconazole therapeutic drug monitoring [J].

Smith, J ;

Safdar, N ;

Knasinski, V ;

Simmons, W ;

Bhavnani, SM ;

Ambrose, PG ;

Andes, D .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (04) :1570-1572

[9] Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients [J].

Trifilio, Steve ;

Pennick, Gennethel ;

Pi, Judy ;

Zook, Jennifer ;

Golf, Mary ;

Kaniecki, Kimberley ;

Singhal, Seema ;

Williams, Stephanie ;

Winter, Jane ;

Tallman, Martin ;

Gordon, Leo ;

Frankfurt, Olga ;

Evens, Andrew ;

Mehta, Jayesh .

CANCER, 2007, 109 (08) :1532-1535

[10] Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients [J].

Troke, Peter F. ;

Hockey, Hans P. ;

Hope, William W. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (10) :4782-4788